Kossel Medtech (Suzhou) Co., Ltd. (“Kossel Medtech”) and Shanghai Rongmai Medical Technology Co., Ltd. (“FuseMedTech”) have officially established a strategic partnership. Both companies will deliver comprehensive integrated solutions for peripheral vascular intervention, fostering deep collaboration across global commercialization, clinical program development and technological innovation.
Strategic Alignment to Expand Clinical Access for Peripheral Vascular Implantable Interventional Devices
FuseMedTech specializes in vascular interventional device development, addressing unmet clinical needs through continuous innovation. Its product portfolio is anchored by the FuseVive® Pulmonary Artery Thrombectomy System, covering peripheral vascular embolism, peripheral thrombus removal and hepatic interventional procedures. Drawing on Kossel Medtech’s well‑established commercial channels, clinical education and regulatory access capabilities, FuseMedTech’s innovative domestic devices will reach broader patient populations living with peripheral vascular disease worldwide.
FuseSuper® Peripheral Fibered Embolization Coil (Push able Coil)
Manufactured in‑house by Shanghai Xiaoyu Medical Technology Co., Ltd. (“Xiaoyu Medical”), a wholly‑owned subsidiary of FuseMedTech, the FuseSuper® Peripheral Fibered Embolization Coil (Push‑able Coil) is China’s first domestically‑manufactured push‑able peripheral fibered embolization coil granted marketing clearance by the NMPA.
– Constructed with platinum tungsten alloy and dense fibers, the device delivers excellent radiopacity, MRI compatibility and biocompatibility.
– Offered in 0.018‑inch and 0.035‑inch delivery systems. A comprehensive size and shape portfolio meets diverse clinical demands. Its unique bi‑hemispherical geometry lowers push‑resistance and minimizes vessel trauma for enhanced procedural safety.
– Proprietary loading and delivery hardware improves handling stability, optimizes coil‑catheter docking, and boosts reliability during coil deployment.
FuseEasy® Peripheral Detachable Fibered Embolization Coil System (Controlled Deployment Coil)
FuseEasy® is Xiaoyu Medical’s flagship peripheral interventional system, indicated for embolization of peripheral aneurysms, arteriovenous fistulas, arteriovenous malformations and other peripheral vascular lesions.
– It adopts an innovative dual‑latch mechanical detachment design for secure connection. Push, retraction and repositioning are permitted prior to deployment, enabling precise, controlled deployment and reducing the risk of unintended premature detachment.
– Variable‑diameter multi‑segment push wire with PTFE coating balances column strength and trackability. It maintains reliable push‑and‑pull performance within tortuous, complex vasculature to streamline workflow.
– Supports both 0.018‑inch and 0.035‑inch platforms, with 2D, Cross and 3D coil configurations across 98 total configurations. It addresses the full embolism workflow: target vessel occlusion, aneurysm basket framing, dense packing and final contour filling, delivering versatile options for peripheral embolization cases.
FuseVive® Pulmonary Artery Thrombectomy System
Developed in‑house by FuseMedTech, the FuseVive® system features a minimally‑invasive “large‑bore aspiration + mechanical thrombectomy” workflow for safe, efficient removal of large thrombus within the main pulmonary artery and its major branches. Key clinical benefits:
– Robust Thrombus Clearance: Proprietary dual‑set disc geometry conforms to native pulmonary artery anatomy and improves mural thrombus removal efficacy.
– Intra‑procedural Bleeding Control: Adaptive hemostasis valve minimizes unnecessary blood loss and enhances patient safety.
– High‑Performance Aspiration: Volume‑calibrated aspirator pairs with the large‑bore aspiration catheter to deliver consistent high negative pressure. It reduces catheter clogging and shortens procedure duration.
– Simplified Workflow: Streamlined device design supports intuitive handling, improves operating efficiency and flattens the operator learning curve.
Ecosystem Expansion & Continuous Platform Advancement
Kossel Medtech pursues its dual‑focus strategy of in‑house innovation and ecosystem integration, expanding its pan‑vascular interventional footprint through strategic acquisitions and industry partnerships.
Through in‑house strategic acquisitions, Kossel Medtech has integrated Biotriton Medical and Xinzhi Medical. Biotriton brings peripheral intravascular ultrasound (IVUS) technology, completing the full care pathway of “imaging assessment → targeted intervention”. Xinzhi Medical develops drug‑coated balloons with both sirolimus‑ and paclitaxel‑based formulations, strengthening Kossel Medtech’s market position for “implant‑free coronary intervention”.
For external alliances, Kossel Medtech has signed strategic agreements with Innomed and Silvan Medical, securing exclusive overseas distribution rights for the Python peripheral drug‑coated balloon (DCB) and Clothoid vascular closure device, accelerating global market access for China‑origin innovations. Kossel Medtech’s platform capabilities are globally recognized, with deep‑running joint projects alongside industry leaders Abbott and Medtronic covering R&D, clinical development and commercialization, enabling mutual knowledge and resource exchange between domestic innovation and global healthcare stakeholders.
This collaboration marks a major milestone for Kossel Medtech’s ecosystem build‑out. It broadens the company’s peripheral intervention product portfolio and advances its vision of delivering a complete one‑stop peripheral interventional solution. As the partnership evolves, both parties will explore further joint innovation, bring diverse interventional treatment options to clinicians worldwide, benefit larger patient cohorts, and drive high‑quality sustainable progress within China’s peripheral intervention sector.